Since ReMI can occur through a variety of mechanisms such as acute stent thrombosis of the culprit lesion, excessive intimal proliferation of stented vessels, and plaque rupture of new atherosclerotic lesions, a detailed analysis for the mechanism of ReMI is ideal.
Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial.
Accordingly, the purpose of the present study was to evaluate the impact of stent designs on acute stent recoil after new generation drug-eluting stent implantation.
Acute stent recoil has been often observed following stent delivery balloon deflation in coronary arteries and the recoil rate varies by stent design.
Drug-eluting stents (DES) have reduced ISR, but generate healing-related issues or hypersensitivity reactions, leading to an increased risk of late acute stent thrombosis.
Immediate and acute stent recoil has been observed following balloon deflation in normal and diseased coronary arteries, and the degree varies by stent design.
Concern regarding the rate of delayed acute stent thrombosis associated with drug-eluting stent (DES) treatment has resulted in upward revision of the advised duration of dual antiplatelet therapy after DES implantation by both European and United States guideline writing committees.
We aimed to investigate the influence of stent strut thickness and design on acute stent strut apposition (SSA) immediately following drug-eluting stent (DES) implantation using optical coherence tomography (OCT), a technique with higher resolution and fewer artefacts than intravascular ultrasound.
In patients with STEMI, bivalirudin use resulted in decreased cardiac mortality (risk ratio [RR] 0.70, 95% confidence interval [CI] 0.50 to 0.97, p = 0.03) compared with heparin plus GP IIb/IIIa inhibitors but an increase in definite stent thrombosis at 30 days (RR 1.88, 95% CI 1.09 to 3.24, p = 0.02) driven by an increase in acute stent thrombosis (RR 5.48, 95% CI 2.30 to 13.07, p = 0.0001).
(4) The effect is transient and also most pronounced on day 3. Previous research focussed on P2Y12-mediated platelet inhibition in resuscitated patients with therapeutic hypothermia and most studies revealed reduced or blunted effects of these drugs in this setting, indicating a potentially increased risk of acute stent thrombosis.
